Celgene Corporation for cancer drug Revlimid agreement with Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation regarding generic version of Revlimid (lenalidomide capsules) in the US. Revlimid is used in the treatment of cancer. " NSE 0.79 % along with one of its wholly-owned subsidiaries today announced that they have reached an agreement with Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation regarding submission of an abbreviated new drug application (ANDA) for a generic version of Revlimid (lenalidomide capsules) in the US,"